Entrada Therapeutics (TRDA) announced that the FDA has lifted the clinical hold on ENTR-601-44 and provided authorization to initiate ELEVATE-44-102, a Phase 1b multiple ascending dose clinical study of ENTR-601-44 for the potential treatment of Duchenne muscular dystrophy in adult patients with a confirmed mutation in the DMD gene amenable to exon 44 skipping.
The global ELEVATE-44 program will cover a broad population of patients with DMD and support evaluation of ENTR-601-44 in patients with both early and advanced disease.
For More Such Health News, visit rttnews.com.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.